Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Shows Off R&D Progress With A Pain Franchise Built On New Mechanisms

Executive Summary

With galcanezumab for cluster headaches and migraine and tanezumab for osteoarthritis, lower back pain and cancer pain, Lilly soon could have an up-and-running pain franchise bolstering its long-term, internal R&D strategy.

Advertisement

Related Content

Can Lilly’s Cluster Headache Data Differentiate Its CGRP Inhibitor?
Opioid Hearing: Senators Want Speed, But Agency Heads Stress Time, Effort
Lilly Pays Nearly $1bn To Regain Migraine Candidate It Once Sold For $1m
With Baricitinib, Lilly Hopes To Succeed Where Pfizer Has Struggled
Pfizer/Lilly And J&J Are Readying NGF Inhibitors For Phase III
Pfizer Plans To Restart Tanezumab Trials In 2014
Anti-NGF Trials Might Resume With Very Narrow Patient Populations
Regeneron, J&J, AstraZeneca Pull Plug On NGF Inhibitors In Development For Pain Indications
Future Appears Grim For Pfizer's Tanezumab With Ostearthritis Trial Stopped
Merck Gets A Headache: Unexpectedly Halts Development Of Migraine Drug

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057676

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel